Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 8/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 2/20 | 0.39 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4B | O94953 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502454 | 0.86 | KDM4E (0.51) | KDM4EAURKAALKBH3NQO1NQO2 | |
| SCHEMBL3500007 | 0.84 | AURKA (0.43) | KDM4EAURKAALKBH3KDM4AKDM4B | |
| SCHEMBL3500914 | 0.83 | STK33 (0.40) | KDM4EAURKAALKBH3KDM4AKDM4B | |
| SCHEMBL3502120 | 0.82 | AURKA (0.53) | KDM4EAURKAALKBH3POLBALOX15 | |
| SCHEMBL3501780 | 0.81 | AURKA (0.46) | KDM4EAURKAALKBH3KDM4AKDM4B | |
| SCHEMBL1054586 | 0.75 | AURKA (0.53) | KDM4EAURKAALKBH3POLBALOX15 | |
| SCHEMBL4305932 | 0.74 | AURKA (0.52) | KDM4EAURKAALKBH3POLBALOX15 | |
| SCHEMBL3502114 | 0.73 | BCHE (0.50) | KDM4EAURKAALKBH3 | |
| SCHEMBL3502287 | 0.73 | HTR3A (0.50) | KDM4EAURKAALKBH3 | |
| SCHEMBL3501534 | 0.73 | BCHE (0.52) | KDM4EAURKAALKBH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-6800760-B2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-6762194-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | CHIRON CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | KDM4E 4563/4885AURKA 1124/4885CHEK1 3447/4885 |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | VEGFA, FLT1, KDR | KDM4E 3745/4885AURKA 265/4885CHEK1 1308/4885 |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | KDR, FLT4, FLT1 | KDM4E 776/4885AURKA 30/4885CHEK1 633/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | KDM4E 4563/4885AURKA 1124/4885CHEK1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.